Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection

Journal of Medical Virology

Volumn 56, Issue 2, 1998, Pages 159-167

  Reinhardt, Barbara ^a   Jaspert, Robert ^b   Niedrig, Matthias ^b   Kostner, Christian ^c   L'age Stehr, Johanna ^b  

^a UNIVERSITY OF ULM   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c Brahms Diagnostica   (Germany)

Author keywords

2 microglobulin; 17D viremia; CD8+ T cells; Neopterin; Neutralizing antibodies

Indexed keywords

BETA 2 MICROGLOBULIN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEOPTERIN; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; VIRUS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIREMIA; VIRUS CULTURE; VIRUS INFECTION; YELLOW FEVER FLAVIVIRUS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MIDDLE AGED; NEOPTERIN; NEUTRALIZATION TESTS; PLAQUE ASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES; VIREMIA; YELLOW FEVER; YELLOW FEVER VIRUS;

EID: 0031655831     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B     Document Type: Article

References (29)

1. Bennink JR, Yewdell JW (1988): Murine cytotoxic T lymphocyte recognition of individual influenza virus proteins. High frequency of non-responder MHC class I alleles. Journal of Experimental Medicine 168:1935-1939.
2. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J (1990): Rapid and simple method for purification of nucleic acids. Journal of Clinical Microbiology 28:495-503.
3. Davis N (1934): On the use of immune serum at various intervals after the inoculation of yellow fever virus into rhesus monkeys. Journal of Immunology 26:361-390.
4. De Madrid AT, Porterfield JS (1969): A simple micro-culture method for the study of group B arboviruses. Bulletin of the World Health Organization 40:113-121.
5. Doherty PC, Zinkernagel RM (1975): A biological role for the major histocompatibility antigens. Lancet 1:1406-1409.
6. dos Santos CN, Post PR, Carvalho R, Ferreira II, Rice CM, Galler R (1995): Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Research 35:35-41.
7. Eichelberger MC, Wang M, Allan W, Webster RG, Doherty PC (1991): Influenza virus RNA in the lung and lymphoid tissue of immunologically intact and CD4-depleted mice. Journal of General Virology 72:1695-1698.
8. Eldadah ZA, Asher DM, Codec MS, Pomeroy KL, Goldfarb LG, Feinstone SM, Levitan H, Gibbs CJ, Gajdusek DC (1991): Detection of flaviviruses by reverse transcriptase polymerase chain reaction. Journal of Medical Virology 33:260-267.
9. Gould EA, Buckley A, Barrett AD, Cammack N (1986): Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. Journal of General Virology 67:591-597.
10. Gray D, Matzinger P (1991): T-cell memory is short-lived in the absence of antigen. Journal of Experimental Medicine 174:969-974.
11. Gray D, Kosco M, Stockinger B (1991): Novel pathways of antigen presentation for the maintenance of memory. International Immunology 3:141-148.
12. Groot H, Ribeiro RB (1962): Neutralizing and haemagglutinationinhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bulletin of the World Health Organization 27: 699-707.
13. Hill AB, Müllbacher A, Parrish C, Coia G, Westaway EG, van Blanden R (1992): Broad cross-reactivity with marked fine specificity in the cytotoxic T cell response to flaviviruses. Journal of General Virology 73:1115-1123.
14. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser A, Reibnegger G, Swetly P, Troppmair J, Wachter J (1984): Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon gamma. Journal of Experimental Medicine 160:310-316.
15. Monath TP (1986): Pathobiology of the flaviviruses. In Schlesinger S, Schlesinger MJ (eds.): "The Togaviridae and Flaviviridae." New York: Plenum Press, pp 375-440.
16. Oehen S, Waldner H, Kündig TM, Hengartner H, Zinkernagel RM (1992): Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. Journal of Experimental Medicine 176:1273-1281.
17. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K (1981): Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bulletin of the World Health Organization 59:895-900.
18. Reed CJ, Munch H (1938): A simple method of estimating fifty percent endpoints. American Journal of Hygiene 27:493-497.
19. Reeves, WC, Hutson, GA, Bellamy, RE, Scrivany, RP (1958): Chronic latent infections of birds with western equine encephalomyelitis virus. Proceedings of the Society for Experimental Biology and Medicine 97:733-736.
20. Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O (1994): MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. Journal of Infectious Diseases 169:807-813.
21. Rosenzweig EC, Babione RW, Wisseman Jr CL (1963): Immunological studies with group B arthropod-borne viruses, IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. American Journal of Tropical Medicine and Hygiene 12:230-235.
22. + cytotoxic T lymphocytes. Journal of Virology 67:801-806.
23. Schlesinger JJ, Brandriss MW, Cropp CP, Monath TP (1986): Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. Journal of Virology 60: 1153-1155.
24. Smithburn KC, Mahaffy AF (1945): Immunization against yellow fever: studies on time of development and duration of induced immunity. American Journal of Tropical Medicine 25:217-223.
25. Theiler M, Smith HH (1937): The use of yellow fever modified by in vitro cultivation for human immunization. Journal of Experimental Medicine 65:787-800.
26. Wheelock EF, Sibley WA (1965): Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. New England Journal of Medicine 273:194-198.
27. Whitton JL, Oldstone MBA (1996): Immune response to viruses. In Fields BN, et al. (eds.): "Fields Virology." Philadelphia: Lippincott-Raven Publishers, pp 345-374.
28. Wisseman Jr CL, Sweet BH (1962): Immunological studies with group B arthropod-borne viruses, III. Response of human subjects to revaccination with 17D strain yellow fever vaccine. American Journal of Tropical Medicine and Hygiene 11:570-575.
29. Yoshida CF, Rouzere CD, Nogueira RM, Lampe E, Travassos-da-Rosa MA, Vanderborght BO, Schatzmayr HG (1992): Human antibodies to Dengue and yellow fever do not react in diagnostic assays for hepatitis C virus. Brazilian Journal of Medicine and Biological Research 25:1131-1135.